Endocyte And Accelerated Approval
Executive Summary
Endocyte CEO Ron Ellis shows no hard feelings that EC145 was turned down for accelerated approval, although he clearly thinks the PRECEDENT trial was well designed and that its median PFS results showed a sufficiently robust improvement over the control to warrant AA. Jason Kantor at RBC is not surprised. He says that, by FDA’s lights, robustness of data can mean different things: magnitude of variance, statistical rigor. “Endocyte showed benefit in a single trial – but that’s not as robust as when a larger Phase III trial confirms your findings.”
You may also be interested in...
Endocyte Targets Folate Receptor Cancers, Devising Innovative Route To Market
With its cash position bolstered by a pair of public equity offerings this year, Endocyte Inc. is pressing ahead with its novel therapeutic and diagnostic platform, initiating late-stage trials in platinum-resistant ovarian cancer (PROC) and non-small-cell lung cancer (NSCLC), with a plan to seek a first approval in Europe.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”